دورية أكاديمية
أعرض في EDS

Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease.

التفاصيل البيبلوغرافية
العنوان: Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease.
المؤلفون: Maganti N; The Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2870 University Avenue, Suite 206, Madison, WI, 53705, USA., Whittier SA; The Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2870 University Avenue, Suite 206, Madison, WI, 53705, USA., Warner EJ; The Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 2870 University Avenue, Suite 206, Madison, WI, 53705, USA. ejwarner@wisc.edu.
المصدر: Journal of ophthalmic inflammation and infection [J Ophthalmic Inflamm Infect] 2024 Apr 16; Vol. 14 (1), pp. 15. Date of Electronic Publication: 2024 Apr 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 101553216 Publication Model: Electronic Cited Medium: Print ISSN: 1869-5760 (Print) Linking ISSN: 18695760 NLM ISO Abbreviation: J Ophthalmic Inflamm Infect Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer
مستخلص: Background: Dupilumab and tralokinumab are interleukin-binding monoclonal antibodies used to treat systemic atopic disease. Use of these medications in management of atopic dermatitis (AD) is known to cause conjunctivitis. Dupilumab therapy has also been associated with more severe ocular surface disease, which has not previously been described in association with tralokinumab. This report describes a case of tralokinumab-associated conjunctivitis and peripheral ulcerative keratitis and reviews the spectrum and proposed mechanisms of ocular surface disease triggered by these medications.
Case Presentation: A 61-year-old male with no rheumatologic or ocular history presented with bilateral papillary conjunctivitis and right eye peripheral ulcerative keratitis (PUK). PUK was arrested using oral corticosteroids and doxycycline, and long-term control of papillary conjunctivitis was achieved using topical tacrolimus ointment, allowing continuation of effective AD management with tralokinumab.
Conclusion: This case report documents ulcerative keratitis occurring in association with tralokinumab therapy for AD, which has previously been described with dupilumab but not tralokinumab. This report demonstrates the need for vigilant ocular surface monitoring for patients on tralokinumab and illustrates successful management and long-term control of adverse ocular events associated with this medication.
(© 2024. The Author(s).)
References: Br J Dermatol. 2022 Dec;187(6):888-899. (PMID: 36082590)
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e612-e614. (PMID: 33657247)
Am Fam Physician. 2020 May 15;101(10):590-598. (PMID: 32412211)
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. (PMID: 34114910)
N Engl J Med. 2016 Dec 15;375(24):2335-2348. (PMID: 27690741)
Exp Eye Res. 2021 Mar;204:108458. (PMID: 33493475)
Surv Ophthalmol. 2021 Nov-Dec;66(6):977-998. (PMID: 33657431)
Br J Dermatol. 2019 Sep;181(3):459-473. (PMID: 30851191)
Ophthalmol Ther. 2019 Sep;8(3):485-490. (PMID: 31230264)
JAMA Dermatol. 2018 Oct 1;154(10):1208-1211. (PMID: 30167653)
Br J Ophthalmol. 2020 Jun;104(6):776-779. (PMID: 31554632)
Int J Dermatol. 2020 Feb;59(2):253-256. (PMID: 31286499)
Acta Derm Venereol. 2019 Apr 1;99(4):375-378. (PMID: 30653240)
Br J Dermatol. 2021 Mar;184(3):450-463. (PMID: 33000503)
Cornea. 2020 Jun;39(6):784-786. (PMID: 31985517)
J Allergy Clin Immunol. 2019 Jan;143(1):135-141. (PMID: 29906525)
Allergol Int. 2019 Jul;68(3):383-384. (PMID: 30718036)
Cornea. 2023 Apr 1;42(4):507-519. (PMID: 36525340)
Cornea. 1990 Jan;9(1):66-73. (PMID: 2297997)
Semin Arthritis Rheum. 2023 Dec;63:152269. (PMID: 37776666)
JAMA Dermatol. 2018 Dec 1;154(12):1485-1486. (PMID: 30347029)
Br J Dermatol. 2021 Mar;184(3):437-449. (PMID: 33000465)
Cornea. 2021 May 1;40(5):584-589. (PMID: 32826648)
J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125-38. (PMID: 9893196)
Eye (Lond). 2021 Dec;35(12):3277-3284. (PMID: 33504973)
J Ophthalmic Vis Res. 2022 Apr 29;17(2):252-275. (PMID: 35765625)
Cornea. 2000 Sep;19(5):625-43. (PMID: 11009315)
Am J Ophthalmol Case Rep. 2020 Aug 05;19:100848. (PMID: 32793843)
Br J Dermatol. 2019 May;180(5):1248-1249. (PMID: 30597515)
Cornea. 2022 Aug 1;41(8):981-985. (PMID: 34928552)
J Dermatolog Treat. 2021 Nov;32(7):737-740. (PMID: 31888394)
Transl Vis Sci Technol. 2020 Feb 25;9(3):29. (PMID: 32742759)
Ophthalmology. 2022 May;129(5):561. (PMID: 35461527)
J Cutan Med Surg. 2017 May/Jun;21(3):227-236. (PMID: 28300440)
Lancet. 2006 Aug 26;368(9537):733-43. (PMID: 16935684)
Lancet. 2017 Jun 10;389(10086):2287-2303. (PMID: 28478972)
Arch Soc Esp Oftalmol (Engl Ed). 2019 Aug;94(8):396-399. (PMID: 31178231)
تواريخ الأحداث: Date Created: 20240416 Latest Revision: 20240425
رمز التحديث: 20240425
مُعرف محوري في PubMed: PMC11021381
DOI: 10.1186/s12348-024-00394-1
PMID: 38625674
قاعدة البيانات: MEDLINE
الوصف
تدمد:1869-5760
DOI:10.1186/s12348-024-00394-1